Table 3.
Rates of AKI by Stage and Underlying Cause Among Patients Receiving CAR-T Therapy
| Parameter | Value |
|---|---|
| Baseline Scr, mg/dLa | |
| Patients without AKI (n = 63) | 0.8 [0.6–0.9] |
| Patients with AKI (n = 15) | 0.8 [0.6–1.0] |
| Peak Scr, mg/dLa | |
| Patients without AKI (n = 63) | 0.9 [0.8–1.1] |
| Patients with AKI (n = 15) | 1.4 [1.1–2.1] |
| Time to peak, da | |
| Patients without AKI (n = 63) | 5 [4–9] |
| Patients with AKI (n = 15) | 10 [6–12] |
| Incidence of AKI by KDIGO stage | |
| Any AKI stageb | 15/78 (19%) |
| AKI stage 1 | 7/78 (9%) |
| AKI stage 2 | 2/78 (3%) |
| AKI stage 3 | 6/78 (8%) |
| Cause | |
| Decreased kidney perfusion (n = 8) | |
| No cytokine release syndrome | 1/8 |
| Cytokine release syndrome stage 1 | 3/8 |
| Cytokine release syndrome stage 2 | 3/8 |
| Cytokine release syndrome stage 3 | 1/8 |
| Acute tubular necrosis (n = 6) | |
| Cytokine release syndrome stage 1 | 0/6 |
| Cytokine release syndrome stage 2 | 1/6 |
| Cytokine release syndrome stage 3 | 2/6 |
| Cytokine release syndrome stage 4 | 3/6 |
| Urinary obstruction (n = 1) | |
| No cytokine release syndromec | 1/1 |
Abbreviations: AKI, acute kidney injury; ATN, acute tubular necrosis; CAR-T, chimeric antigen receptor T cell; KDIGO, Kidney Disease: Improving Global Outcomes; Scr, serum creatinine.
a
Median [interquartile range] and count (percentage).
b
Cause of AKI by stage: stage 1, 6 from decreased kidney perfusion, 1 from ATN; stage 2, 2 from decreased kidney perfusion, AKI stage 3, 5 from ATN, 1 from obstruction.
c
Resulted from diffuse large B-cell lymphoma progression.